Indications: Mexclav is indicated for the treatment of infections caused by sensitive bacteria, including:

Pharyngitis/Tonsillitis caused by Streptococcus pyogenes
Acute bacterial otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (beta‑lactamase producing strains), or Streptococcus pyogenes
Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non beta‑lactamase producing strains)
Lower respiratory tract infections including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta‑lactamase producing strains), Klebsiella spp., Staphylococcus aureus (penicillinase and non‑penicillinase producing strains), Streptococcus pyogenes, E. coli
Acute bacterial exacerbation of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta‑lactamase negative strains), or Haemophilus parainfluenzae (beta‑lactamase negative strains)
Uncomplicated skin and skin‑structure infections caused by Staphylococcus aureus (including beta‑lactamase producing strains) or Streptococcus pyogenes
Uncomplicated urinary tract infections caused by E. coli or Klebsiella pneumoniae
Bone and joint infections caused by Staphylococcus aureus (penicillinase and non‑penicillinase producing strains)
Uncomplicated gonorrhea caused by penicillinase‑producing and non‑penicillinase producing strains of Neisseria gonorrhoeae
Early Lyme disease (erythema migrans) caused by Borrelia burgdorferi
Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, E. coli, Haemophilus influenzae (including ampicillin‑resistant strains), and Klebsiella spp.
Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin‑resistant strains), Neisseria meningitidis, and Staphylococcus aureus (penicillinase and non‑penicillinase producing strains)
Switch therapy (injectable to oral)

Pharmacology: Cefuroxime is a bactericidal second‑generation cephalosporin antibiotic active against a wide range of Gram‑positive and Gram‑negative organisms, including many beta‑lactamase producing strains. It inhibits bacterial cell wall synthesis by interfering with the transpeptidation process. Clavulanic acid is a naturally derived beta‑lactamase inhibitor produced by Streptomyces clavuligerus. It irreversibly binds to beta‑lactamase enzymes, inactivating them, and protects cefuroxime from degradation, enabling treatment of infections caused by beta‑lactam resistant bacteria.

Dosage & Administration:

Adolescents and adults (≥13 years):
- Pharyngitis/Tonsillitis: 250 mg twice daily for 5–10 days
- Acute maxillary sinusitis: 250 mg twice daily for 10 days
- Acute exacerbation of chronic bronchitis: 250–500 mg twice daily for 10 days
- Secondary bacterial infections of acute bronchitis: 250–500 mg twice daily for 5–10 days
- Skin/skin‑structure infections: 250–500 mg twice daily for 10 days
- Urinary tract infections: 250 mg twice daily for 7–10 days
- Gonorrhea: 1000 mg single dose
- Community‑acquired pneumonia: 250–500 mg twice daily for 5–10 days
- MDR Typhoid fever: 500 mg twice daily for 10–14 days
- Early Lyme disease: 500 mg twice daily for 20 days
Pediatric patients (3 months–12 years):
- Pharyngitis/Tonsillitis: 20 mg/kg/day in two divided doses for 5–10 days
- Acute otitis media: 30 mg/kg/day in two divided doses for 10 days
- Acute maxillary sinusitis: 30 mg/kg/day in two divided doses for 10 days
- Impetigo: 30 mg/kg/day in two divided doses for 10 days